Compare ACHR & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACHR | GRFS |
|---|---|---|
| Founded | 2018 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.2B |
| IPO Year | N/A | 2006 |
| Metric | ACHR | GRFS |
|---|---|---|
| Price | $8.47 | $8.81 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 2 |
| Target Price | ★ $12.14 | $10.15 |
| AVG Volume (30 Days) | ★ 36.5M | 442.6K |
| Earning Date | 02-26-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | N/A | ★ $8,821,017,248.00 |
| Revenue This Year | N/A | $5.36 |
| Revenue Next Year | N/A | $5.15 |
| P/E Ratio | ★ N/A | $17.98 |
| Revenue Growth | N/A | ★ 7.31 |
| 52 Week Low | $5.48 | $6.19 |
| 52 Week High | $14.62 | $11.14 |
| Indicator | ACHR | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 51.80 | 41.49 |
| Support Level | $8.42 | $9.17 |
| Resistance Level | $9.24 | $9.57 |
| Average True Range (ATR) | 0.44 | 0.22 |
| MACD | 0.11 | -0.03 |
| Stochastic Oscillator | 58.97 | 5.13 |
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.